Marie Ange Mouret‐Reynier

Author

Centre Léon Bérard

Also Known As

Marie A Mouret-Reynier, Marie A. Mouret-Reynier, Marie Ange Mouret-Reynier, Marie Ange Mouret‐Reynier

Publications

721

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Centre Jean Perrin Institut Claudius Regaud Institut Curie Institut Jean Godinot

About

Marie Ange Mouret‐Reynier is an author at Centre Léon Bérard specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	281
2	Obstetrics	3	3	229
3	Health Sciences	1	1	15
4	Public Health	1	1	180
5	Epidemiology	1	1	180

Marie Ange Mouret‐Reynier

Publications

708

Citations

H-Index

Page 1

	Year	Citations
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Amélie Darlix, G. Louvel, Julien Fraisse, British Journal of Cancer	2019	206
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016 Élise Deluche, Alison Antoine, Thomas Bachelot, European Journal of Cancer Metastatic Breast CancerBreast OncologyCancer EpidemiologyMedicineEpidemiology Of Cancer	2020	180
Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse Émilie Thivat, Sophie Thérondel, Olivier Lapirot, BMC Cancer	2010	126
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial Philipp Harter, Marie Ange Mouret‐Reynier, Sandro Pignata, Gynecologic Oncology	2021	85
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort Amélie Darlix, G. Louvel, Julien Fraisse, European Journal of Cancer Neuro-oncologySurgical OncologyBreast OncologyMedicineCancer Management	2019	52
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer Suzette Delaloge, Sylvain Dureau, Véronique D’Hondt, European Journal of Cancer Survival OutcomesOncologyBreast OncologyMedicineNeoadjuvant Letrozole	2022	34
Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study Olivia Le Saux, Audrey Lardy-Cléaud, Sophie Frank, European Journal of Cancer Endocrine OncologyBreast OncologyOncologyCancer ManagementClinical Trials	2019	15
Survival outcomes of metastatic breast cancer patients by germline <i>BRCA1/2</i> status in a large multicenter real‐world database Audrey Mailliez, Véronique D’Hondt, Amélie Lusque, International Journal of Cancer	2022	10

Page 1